Table 10Placebo-controlled monotherapy trials contributing to MADRS meta-analyses

Author, YearSubjectsNAugmentationDurationOutcomes
AstraZeneca 200716818-65 years old, DSM-IV diagnosis of MDD, HAM-D score >=22, HAM-D item 1 score >=2471Placebo

Quetiapine 50-300 mg/day

Escitalopram 10-20 mg/day
9 weeksMADRS % Remitted:
Quetiapine vs Placebo - RR = 1.01 (0.75, 1.37)

MADRS % Responded:
Quetiapine vs Placebo – RR = 1.18 (0.97, 1.45)
AstraZeneca 2008169Age >=66, DSM-IV diagnosis of MDD confirmed by MINI. HAM-D total score >=22, HAM-D item 1 score >=2 at both enrollment and randomization.338Placebo 50-300 mg/day

Quetiapine 50-300 mg/day
9 weeksMADRS % Remitted:
Quetiapine vs Placebo - RR = 2.48 (1.70, 3.62)

MADRS % Responded:
Quetiapine vs Placebo - RR = 2.11 (1.63, 2.71)
Bortnick, 201117018 -65 years old, MDD confirmed by the MINI and DSM-IV, have a HAM-D >= 22, HAM-D item1 score >= 2 at both enrollment and randomization310Placebo 50-300 mg/day

Quetiapine 50-300 mg/day
8 weeksMADRS % Remitted:
Quetiapine vs Placebo - RR = 1.39 (0.97, 1.98)

MADRS % Responded:
Quetiapine vs Placebo - RR = 1.29 (1.05, 1.59)
Cutler et al. 200917118-65 years old, diagnosed MDD, HAM-D total score >=22, HAM-D item 1 score >=>= at enrollment and randomization612Placebo

Quetiapine 50-150 mg/day

Quetiapine 50-300 mg/day

Duloxetine 60 mg/day
6 weeksMADRS % Remitted:
Quetiapine vs Placebo - RR = 1.43 (1.03, 2.06)

MADRS % Responded:
Quetiapine vs Placebo - RR = 1.51 (1.20, 1.91)
Weisler et al. 200917218-65, output, MDD, HAM-D item 17>=22, HAM-D item 1>=2723Placebo

Quetiapine 50 mg/day

Quetiapine 50-150 mg/day

Quetiapine 50-300 mg/day
6 weeksMADRS % Remitted:
Quetiapine vs Placebo - RR = 1.27 (0.89, 1.82)

MADRS % Responded:
Quetiapine vs Placebo – RR = 1.58 (1.24, 2.02)

DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, 4th editon; HAM-D = Hamilton Depression Rating Scale; MADRS = Montgomery-Asberg Depression Rating Scale; MDD = major depressive disorder

From: Results

Cover of Off-Label Use of Atypical Antipsychotics: An Update
Off-Label Use of Atypical Antipsychotics: An Update [Internet].
Comparative Effectiveness Reviews, No. 43.
Maglione M, Maher AR, Hu J, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.